Minilik Angagaw
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Melanoma and MAPK Pathways, Synthesis and biological activity, Prostate Cancer Treatment and Research, Cancer Mechanisms and Therapy
Most-Cited Works
- → Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors(2013)676 cited
- → Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten -Deficient Mouse Model of Prostate Cancer(2009)76 cited
- → Down‐regulation of the Notch pathway mediated by a γ‐secretase inhibitor induces anti‐tumour effects in mouse models of T‐cell leukaemia(2009)75 cited
- → MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis(2014)53 cited
- → A Quantitative Volumetric Micro-Computed Tomography Method to Analyze Lung Tumors in Genetically Engineered Mouse Models(2009)49 cited
- → Purine derivatives as potent γ-secretase modulators(2010)35 cited
- → PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models(2011)32 cited
- → Transferring Luminex® cytokine assays to a wall-less plate technology: Validation and comparison study with plasma and cell culture supernatants(2016)31 cited
- → Fluorinated piperidine acetic acids as γ-secretase modulators(2009)29 cited
- → Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors(2012)27 cited